Table 2.
Proportion of women at each visit who were taking or not taking a secondary prevention medication following an adjudicated CHD diagnosis. For the 2nd and 3rd visit after the first visit following a CHD diagnosis, the proportion of women attending the visit is displayed to reflect use of the drug at the previous visit and drug use at that visit.
| Drug class | On drug at 1st visit after Diagnosis | n/N* Percent (95% CI) attending 1st visit |
On drug at 2nd visit after diagnosis | n/N* Percent (95% CI) attending 2nd visit |
On drug at 3rd visit after diagnosis | n/N* Percent (95% CI) Attending 3rd visit |
|---|---|---|---|---|---|---|
| Statin | Yes | 1039/1669 62.3 (59.9, 64.6) |
Yes | 371/423 87.7 (84.2, 90.7) |
Yes | 86/96 89.6 (81.7, 94.9) |
| No | 10/96 10.4 (5.1, 18.3) |
|||||
| No | 52/423 12.3 (9.3, 15.8) |
Yes | 10/15 66.7 (38.4, 88.2) |
|||
| No | 5/15 33.3 (11.8, 61.6) |
|||||
| Statin | No | 630/1669 37.8 (35.4, 40.1) |
Yes | 134/298 45.0 (39.2, 50.8) |
Yes | 43/51 84.3 (71.4, 93.0) |
| No | 8/51 15.7 (7.0, 28.6) |
|||||
| No | 164/298 55.0 (49.2, 60.8) |
Yes | 26/65 40.0 (28.0, 52.9) |
|||
| No | 39/65 60.0(47.1, 72.0) |
|||||
| Aspirin | Yes | 1240/1669 74.3 (72.1, 76.4) |
Yes | 456/542 84.1 (80.8, 87.1) |
Yes | 123/147 83.7 (76.7, 89.3) |
| No | 24/147 16.3 (10.8, 23.3) |
|||||
| No | 86/542 15.9 (12.9, 19.2) |
Yes | 16/25 64.0 (42.5, 82.0) |
|||
| No | 9/25 36.0 (18.0, 57.5) |
|||||
| Aspirin | No | 4297/1669 25.7 (23.6, 27.9) |
Yes | 94/179 52.5 (44.9, 60.0) |
Yes | 22/25 88.0 (68.8, 97.5) |
| No | 3/25 12.0 (2.6, 31.2) |
|||||
| No | 85/179 47.5 (40.0, 55.1) |
Yes | 13/30 43.3 (25.5, 62.6) |
|||
| No | 17/30 56.7 (37.4, 74.5) |
|||||
| Beta-blocker | Yes | 965/1669 57.8 (55.4, 60.2) |
Yes | 330/385 85.7 (81.8, 89.1) |
Yes | 88/100 88.0 (80.0, 93.6) |
| No | 12/100 12.0 (6.4, 20.0) |
|||||
| No | 55/385 14.3 (11.0, 18.2) |
Yes | 5/15 33.3 (11.8, 61.6) |
|||
| No | 10/15 66.7 (38.4, 88.2) |
|||||
| Beta-blocker | No | 704/1669 42.2 (39.8, 44.6) |
Yes | 84/336 25.0 (20.5, 30.0) |
Yes | 13/18 72.2 (46.5, 90.3) |
| No | 5/18 27.8 ( 9.7, 53.5) |
|||||
| No | 252/336 75.0 (70.0, 79.5) |
Yes | 17/94 18.1 (10.9, 27.4) |
|||
| No | 77/94 81.9 (72.6, 89.1) |
|||||
| ACEI/ARB | Yes | 667/1669 40.0 (37.6, 42.4) |
Yes | 186/245 75.9 (70.1, 81.1) |
Yes | 39/52 75.0 (61.1, 86.0) |
| No | 13/52 25.0 (14.0, 39.0) |
|||||
| No | 59/245 24.1 (18.9, 29.9) |
Yes | 2/9 22.2 (2.8, 60.0) |
|||
| No | 7/9 77.8 (40.0, 97.2) |
|||||
| ACEI/ARB | No | 1002/1669 60.0 (57.6, 62.4) |
Yes | 90/476 18.9 (15.5, 22.7) |
Yes | 17/26 65.4 (44.3, 82.8) |
| No | 9/26 34.6 (17.2, 55.7) |
|||||
| No | 386/476 81.1 (77.3, 84.5) |
Yes | 29/140 20.7 (14.3, 28.4) |
|||
| No | 111/140 79.3 (71.6, 85.7) |
ACEI/ARB=Angiotensin converting enzyme inhibitor/angiotensin-II receptor blocker
*
n/N = number meeting criteria/number attending that visit